Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1986 Nov;32(5):383-424.
doi: 10.2165/00003495-198632050-00001.

Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy

Review

Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy

D M Campoli-Richards et al. Drugs. 1986 Nov.

Abstract

Inosine pranobex is a synthetic compound formed from the p-acetamido benzoate salt of N-N dimethylamino-2-propanol and inosine in a 3:1 molar ratio. It has been reported to exert antiviral and antitumour activities in vivo which are secondary to an immunomodulating effect, and early results suggest beneficial clinical effects in several diseases and infections including mucocutaneous Herpes simplex infections, subacute sclerosing panencephalitis, genital warts, influenza, zoster, and type B viral hepatitis, as well as in homosexual men with persistent generalised lymphadenopathy. However, many of the studies have been preliminary in nature and deficient in design or in the reporting of their results. One must therefore conclude that while inosine pranobex may prove to be a valuable and innovative therapy for a number of diseases and infections for which no satisfactory therapy exist, further long term well controlled studies in larger numbers of patients are required before definitive conclusions about the efficacy of inosine pranobex in these disorders will be possible.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Arch Dermatol. 1983 Jun;119(6):463-7 - PubMed
    1. Stat Med. 1984 Jul-Sep;3(3):225-37 - PubMed
    1. Recenti Prog Med. 1984 Dec;75(12):1081-8 - PubMed
    1. Int J Immunopharmacol. 1983;5(1):99-103 - PubMed
    1. Int J Immunopharmacol. 1984;6(4):321-8 - PubMed

LinkOut - more resources